Targeting Mucus Obstruction to Improve Lung Health
AER-01: a novel approach to treating muco-obstructive lung disease
Treatment for Mucus Obstructions Has Been a Serious Challenge in Chronic Lung Diseases
The Mucus Problem
Mucus plugs block airways in up to half of moderate to severe COPD and asthma patients, reducing lung function, impairing quality of life, and increasing mortality. However, there are currently no effective mucolytic treatments for these patients. In the US alone, over 5 million people with COPD and 1.5 million with asthma are affected by mucus plugs.
The Solution
AER-01 is the first therapy designed to liquify mucus plugs by cleaving the chemical bonds that thicken mucus. AER-01 opens the airways, restores airflow, and reduces inflammation. AER-01 may also clear the path for standard therapies like bronchodilators and steroids to reach otherwise blocked regions of the lung.
Giving Patients the
Ability To Breathe Again
For individuals with severe COPD and asthma, mucus plugs can significantly hinder breathing. AER-01 is the first inhaled therapy developed to clear mucus blockages, helping to break the cycle of inflammation and restore the freedom to breathe. By opening the airways, AER-01 also enables other treatments to reach deeper into the lungs.
Advancing Science, Transforming Lives
Phase 2a Clinical Trial
of AER-01
Aer Therapeutics has initiated a proof-of-concept clinical study for AER-01 in COPD and asthma.
The Science Behind AER-01
Plugged airway
Open airway
Clearing Mucus Plugs
AER-01 works by cleaving the chemical bonds that tangle long mucin strands, making mucus thick and elastic. AER-01 is the first mucus-targeting drug for COPD and asthma.